Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers

Breast Cancer Research and Treatment

Volumn 143, Issue 3, 2014, Pages 517-529

  Loud, Jennifer T ^a   Gierach, Gretchen L ^a   Veenstra, Timothy D ^b,c   Falk, Roni T ^a   Nichols, Kathryn ^d   Guttmann, Allison ^a   Xu, Xia ^b,c   Greene, Mark H ^a   Gail, Mitchell H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WESTAT   (United States)

Author keywords

BRCA1 2; Ductal lavage supernatant; Estrogen metabolites; Estrogens; LC MS MS; Nipple aspirate fluid; Parent estrogens; Postmenopausal

Indexed keywords

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOGENESIS; ESTRADIOL; ESTRONE; FEMALE; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NIPPLE ASPIRATE FLUID; POSTMENOPAUSE; PREMENOPAUSE; TANDEM MASS SPECTROMETRY;

EID: 84894056029     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2821-6     Document Type: Article

References (42)

1. Endogenous Hormones Breast Cancer Collaborative Group (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95(16):1218-1226
2. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350(9084):1047-1059 Erratum appears in Lancet 1997 Nov 15; 350(9089):1484
3. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283(4):485-491
4. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. JAMA 291(14):1701-1712
5. Beral V, Banks E, Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360(9337):942-944
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288(3):321-333
7. Westerlind KC, Gibson KJ, Evans GL, Turner RT (2000) The catechol estrogen, 4-hydroxyestrone, has tissue-specific estrogen actions. J Endocrinol 167(2):281-287
8. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3):270-282
9. Harvell DM, Strecker TE, Tochacek M, Xie B, Pennington KL, McComb RD, Roy SK, Shull JD (2000) Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci USA 97(6):2779-2784
10. Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92(9):3650-3657
11. Turan VK, Sanchez RI, Li JJ, Li SA, Reuhl KR, Thomas PE, Conney AH, Gallo MA, Kauffman FC, Mesia-Vela S (2004) The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17beta-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16alpha-hydroxyestradiol, and 4-hydroxyestrone. J Endocrinol 183(1):91-99
12. Yager JD, Liehr JG (1996) Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 36:203-232
13. Yang X, Edgerton SM, Kosanke SD, Mason TL, Alvarez KM, Liu N, Chatterton RT, Liu B, Wang Q, Kim A (2003) Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res 63(10):2425-2433
14. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86(3-5):477-486
15. Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr 27:95-112
16. Cavalieri EL, Rogan EG (2011) Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol 125:169-180
17. Zhu BT, Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19(1):1-27
18. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, Veenstra TD et al (2012) Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 104(4):326-339
19. Falk R, Gentzschein E, Stanczyk F, Garcia-Closas M, Figueroa J, Ioffe O, Lissowska J, Brinton L, Sherman M (2012) Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. Breast Cancer Res Treat 131(1):287-294
20. Taioli E, Im A, Xu X, Veenstra T, Ahrendt G, Garte S (2010) Comparison of estrogens and estrogen metabolites in human breast tissue and urine. Reprod Biol Endocrinol 8(1):93
21. Castagnetta LAM, Granata OM, Traina A, Ravazzolo B, Amoroso M, Miele M, Bellavia V, Agostara B, Carruba G (2002) Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res 8(10):3146-3155
22. Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL (2008) The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 122(9):1949-1957
23. Yaghjyan L, Colditz (2011) Estrogens in the breast tissue: a systematic review. Cancer Causes Control 22(4):529-540
24. Chatterton R Jr, Parker N, Habe-Evans M, Bryk M, Scholtens D, Khan S (2010) Breast ductal lavage for assessment of breast cancer biomarkers. Horm Cancer 1(4):197-204
25. Berstein LM (2008) Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Futur Oncol 4(1):23-39
26. Lee EY (2008) Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones. Curr Opin Obstet Gynecol 20(1):68-73
27. Hu Y (2009) BRCA1, hormone, and tissue-specific tumor suppression. Int J Biol Sci 5(1):20-27
28. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat M-L, Gyorki DE, Ward T, Partanen A et al (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8):907-913
29. Roy R, Chun J, Powell SN (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12(1):68-78
30. Chatterton RT Jr, Geiger AS, Gann PH, Khan SA (2003) Formation of estrone and estradiol from estrone sulfate by normal breast parenchymal tissue. J Steroid Biochem Mol Biol 86(2):159-166
31. Bhandare D, Nayar R, Bryk M, Hou N, Cohn R, Golewale N, Parker NP, Chatterton RT, Rademaker A, Khan SA (2005) Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomarkers Prev 14:2620-2627
32. Khan SA, Bhandare D, Chatterton RT Jr (2005) The local hormonal environment and related biomarkers in the normal breast. Endocr Relat Cancer 12(3):497-510
33. Ernster VL, Wrensch MR, Petrakis NL, King EB, Miike R, Murai J, Goodson WH III, Siiteri PK (1987) Benign and malignant breast disease: initial study results of serum and breast fluid analyses of endogenous estrogens. J Natl Cancer Inst 79(5):949-960
34. Chatterton RT Jr, Geiger AS, Mateo ET, Helenowski IB, Gann PH (2005) Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement. J Clin Endocrinol Metab 90(3):1686-1691
35. Ziegler RG, Faupel-Badger JM, Sue LY, Fuhrman BJ, Falk RT, Boyd-Morin J, Henderson MK, Hoover RN, Veenstra TD, Keefer LK (2010) A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol 121:538-545
36. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG (2007) Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography tandem mass spectrometry. Anal Chem 79(20):7813-7821
37. Loud J, Beckjord E, Nichols K, Peters J, Giusti R, Greene M (2009) Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. BMC Women's Health 9(1):20
38. Gierach GL, Loud JT, Chow CK, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K et al (2010) Mammographic density does not differ between unaffected BRCA1/2 mutation carriers and women at low-to-average risk of breast cancer. Breast Cancer Res Treat 123(1):245-255
39. Loud JT, Thiebaut ACM, Abati AD, Filie AC, Nichols K, Danforth D, Giusti R, Prindiville SA, Greene MH (2009) Ductal lavage in women from BRCA1/2 families: is there a future for ductal lavage in women at increased genetic risk of breast cancer? Cancer Epidemiol Biomark Prev 18(4):1243-1251
40. Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF et al (2001) Ductal lavage for detection of cellular atypia in women at high risk of breast cancer. J Natl Cancer Inst 93(21):1624-1632
41. Chatterton RT, Khan SA, Heinz R, Ivancic D, Lee O (2010) Patterns of sex steroid hormones in nipple aspirate fluid during the menstrual cycle and after menopause in relation to serum concentrations. Cancer Epidemiol Biomark Prev 19(1):275-279
42. Faupel-Badger JM, Fuhrman BJ, Xu X, Falk RT, Keefer LK, Veenstra TD, Hoover RN, Ziegler RG (2010) Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens. Cancer Epidemiol Biomark Prev 19(1):292-300